PDF(Pubmed)
Abstract：
BACKGROUND: Non-Hodgkin lymphoma (NHL) has been identified as a significant contributor to the cancer burden. This study investigates the incidence, mortality, and survival trends of NHL cancer in Brunei Darussalam from 2011 to 2020.
METHODS: This is a registry-based retrospective study using de-identified data from the Brunei Darussalam Cancer Registry on patients diagnosed with NHL from 2011 to 2020 based on the ICD-10 codes C82-86. Statistical methods include descriptive statistics, age-specific and age-standardised incidence (ASIR) and mortality rates (ASMR), and joinpoint regression for trend analysis. Survival analysis was conducted using Kaplan-Meier plots, log-rank test, and Cox Proportional Hazards regression.
RESULTS: From 2011 to 2020, 330 patients were diagnosed with NHL. The majority of patients were males (51.8%) and of Malay descent (82.7%). The age group most diagnosed was 55-74 years (42.3%), with a mean age at diagnosis being 55.1 years. The ASIRs were 12.12 for males and 10.39 per 100,000 for females; ASMRs were 6.11 for males and 4.76 per 100,000 for females. Diffuse large B-cell lymphoma was the most prevalent subtype, accounting for 39.1% of cases. The overall 5-year survival rate was 61.2%, with lower rates observed in older patients and those diagnosed at distant metastasis stage. Furthermore, older age and advanced stage diagnosis significantly increased mortality risk. NHL incidence and mortality rates in Brunei Darussalam remain stable over the period of 10 years, but highlights significant disparities in gender and age.
CONCLUSIONS: The findings emphasize the importance of early detection and tailored treatments, especially for high-risk groups, in managing NHL\'s burden. These insights underline the need for focused healthcare strategies and continued research to address NHL\'s challenges.
METHODS: This is a registry-based retrospective study using de-identified data from the Brunei Darussalam Cancer Registry on patients diagnosed with NHL from 2011 to 2020 based on the ICD-10 codes C82-86. Statistical methods include descriptive statistics, age-specific and age-standardised incidence (ASIR) and mortality rates (ASMR), and joinpoint regression for trend analysis. Survival analysis was conducted using Kaplan-Meier plots, log-rank test, and Cox Proportional Hazards regression.
RESULTS: From 2011 to 2020, 330 patients were diagnosed with NHL. The majority of patients were males (51.8%) and of Malay descent (82.7%). The age group most diagnosed was 55-74 years (42.3%), with a mean age at diagnosis being 55.1 years. The ASIRs were 12.12 for males and 10.39 per 100,000 for females; ASMRs were 6.11 for males and 4.76 per 100,000 for females. Diffuse large B-cell lymphoma was the most prevalent subtype, accounting for 39.1% of cases. The overall 5-year survival rate was 61.2%, with lower rates observed in older patients and those diagnosed at distant metastasis stage. Furthermore, older age and advanced stage diagnosis significantly increased mortality risk. NHL incidence and mortality rates in Brunei Darussalam remain stable over the period of 10 years, but highlights significant disparities in gender and age.
CONCLUSIONS: The findings emphasize the importance of early detection and tailored treatments, especially for high-risk groups, in managing NHL\'s burden. These insights underline the need for focused healthcare strategies and continued research to address NHL\'s challenges.
摘要：
背景：非霍奇金淋巴瘤（NHL）已被确定为癌症负担的重要原因。这项研究调查了发病率，死亡率,2011年至2020年文莱达鲁萨兰国NHL癌症的生存趋势。
方法：这是一项基于注册的回顾性研究，使用文莱达鲁萨兰国癌症注册中心的去识别数据，根据ICD-10代码C82-86，对2011年至2020年诊断为NHL的患者进行研究。统计方法包括描述性统计，年龄特异性和年龄标准化发病率(ASIR)和死亡率(ASMR)，和用于趋势分析的连接点回归。使用Kaplan-Meier图进行生存分析，对数秩检验，和Cox比例风险回归。
结果：从2011年到2020年，330例患者被诊断为NHL。大多数患者是男性（51.8％）和马来人后裔（82.7％）。诊断最多的年龄组为55-74岁（42.3％），诊断时的平均年龄为55.1岁。男性ASIR为12.12，女性为10.39/100,000；男性ASMR为6.11，女性为4.76/100,000。弥漫性大B细胞淋巴瘤是最常见的亚型,占病例数的39.1%。5年生存率为61.2%,在老年患者和远处转移阶段诊断的患者中观察到较低的发生率。此外，高龄和晚期诊断显著增加死亡风险.文莱达鲁萨兰国的NHL发病率和死亡率在10年内保持稳定，但突出了性别和年龄的显著差异。
结论：研究结果强调了早期发现和定制治疗的重要性，尤其是高危人群,管理NHL的负担。这些见解强调了需要有针对性的医疗保健策略和持续的研究来解决NHL的挑战。
方法：这是一项基于注册的回顾性研究，使用文莱达鲁萨兰国癌症注册中心的去识别数据，根据ICD-10代码C82-86，对2011年至2020年诊断为NHL的患者进行研究。统计方法包括描述性统计，年龄特异性和年龄标准化发病率(ASIR)和死亡率(ASMR)，和用于趋势分析的连接点回归。使用Kaplan-Meier图进行生存分析，对数秩检验，和Cox比例风险回归。
结果：从2011年到2020年，330例患者被诊断为NHL。大多数患者是男性（51.8％）和马来人后裔（82.7％）。诊断最多的年龄组为55-74岁（42.3％），诊断时的平均年龄为55.1岁。男性ASIR为12.12，女性为10.39/100,000；男性ASMR为6.11，女性为4.76/100,000。弥漫性大B细胞淋巴瘤是最常见的亚型,占病例数的39.1%。5年生存率为61.2%,在老年患者和远处转移阶段诊断的患者中观察到较低的发生率。此外，高龄和晚期诊断显著增加死亡风险.文莱达鲁萨兰国的NHL发病率和死亡率在10年内保持稳定，但突出了性别和年龄的显著差异。
结论：研究结果强调了早期发现和定制治疗的重要性，尤其是高危人群,管理NHL的负担。这些见解强调了需要有针对性的医疗保健策略和持续的研究来解决NHL的挑战。
